Westin Jenny E, Vercammen Linda, Strome Elissa M, Konradi Christine, Cenci M Angela
Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, Sweden.
Biol Psychiatry. 2007 Oct 1;62(7):800-10. doi: 10.1016/j.biopsych.2006.11.032. Epub 2007 Jul 26.
We examined the activation pattern of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and its dependence on D1 versus D2 dopamine receptors in hemiparkinsonian rats treated with 3,4-dihydroxyphenyl-L-alanine (L-DOPA).
6-Hydroxydopamine-lesioned rats were treated acutely or chronically with L-DOPA in combination with antagonists for D1 or D2 receptors. Development of dyskinesia was monitored in animals receiving chronic drug treatment. Phosphorylation of ERK1/2, mitogen- and stress-activated protein kinase-1 (MSK-1), and the levels of FosB/DeltaFosB expression were examined immunohistochemically.
L-DOPA treatment caused phosphorylation of ERK1/2 in the dopamine-denervated striatum after acute and chronic administration. Similar levels were observed in matrix and striosomes, and in enkephalin-positive and dynorphin-positive neurons. The severity of dyskinesia was positively correlated with phospho-ERK1/2 levels. Phosphorylation of ERK1/2 and MSK-1 was dose-dependently blocked by SCH23390, but not by raclopride. SCH23390 also inhibited the development of dyskinesia and the induction of FosB/DeltaFosB.
L-DOPA produces pronounced activation of ERK1/2 signaling in the dopamine-denervated striatum through a D1-receptor-dependent mechanism. This effect is associated with the development of dyskinesia. Phosphorylated ERK1/2 is localized to both dynorphinergic and enkephalinergic striatal neurons, suggesting a general role of ERK1/2 as a plasticity molecule during L-DOPA treatment.
我们研究了用3,4-二羟基苯丙氨酸(L-多巴)治疗的偏侧帕金森病大鼠细胞外信号调节激酶1和2(ERK1/2)的激活模式及其对D1和D2多巴胺受体的依赖性。
用6-羟基多巴胺损伤的大鼠急性或慢性给予L-多巴,并联合D1或D2受体拮抗剂。监测接受慢性药物治疗动物的运动障碍发展情况。通过免疫组织化学检查ERK1/2、丝裂原和应激激活蛋白激酶-1(MSK-1)的磷酸化以及FosB/DeltaFosB表达水平。
急性和慢性给予L-多巴后,L-多巴治疗导致多巴胺去神经支配纹状体中ERK1/2磷酸化。在基质和纹状体小体以及脑啡肽阳性和强啡肽阳性神经元中观察到相似水平。运动障碍的严重程度与磷酸化ERK1/2水平呈正相关。SCH23390可剂量依赖性地阻断ERK1/2和MSK-1的磷酸化,但雷氯必利不能。SCH23390还抑制运动障碍的发展和FosB/DeltaFosB的诱导。
L-多巴通过D1受体依赖性机制在多巴胺去神经支配的纹状体中产生明显的ERK1/2信号激活。这种效应与运动障碍的发展有关。磷酸化的ERK1/2定位于强啡肽能和脑啡肽能纹状体神经元,表明ERK1/2在L-多巴治疗期间作为可塑性分子具有普遍作用。